Early plasma circulating tumor DNA (ctDNA) changes to predict response to first-line pembrolizumab +/- chemotherapy in non-small cell lung cancer (NSCLC) | NeoGenomics Laboratories

Publication date

Fri, 05/29/2020 - 12:00

Category

Year

Subtitle

ASCO 2020 (Virtual)

File

Early_plasma_circulating_tumor_DNA_ctDNA_changes_to_predict_response_to_first-line_pembrolizumab_plus_chemotherapy_in_non-small_cell_lung_cancer.pdf (342.88 KB)

Division